University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Peter R. Carroll, MD, MPH

Peter R. Carroll, MD, MPH

Associate Director, Strategic Planning and Clinical Services; and Program Leader, Prostate Cancer Program, Helen Diller Family Comprehensive Cancer Center; Associate Dean, School of Medicine; Chair, Department of Urology, UCSF
Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer; Taube Family Distinguished Professorship in Urology, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

My main research interests include identifying clinical and pathologic determinants of prostate cancer recurrence, progression, and mortality; discovering novel biomarkers for prostate cancer diagnostics and prognostics; developing evidence-based guidelines for improved management of prostate cancer patients; and examining the impact of lifestyle on health-related quality of life and survivorship among men with prostate cancer. Since 1995, I have been PI of CaPSURE™, a national disease registry study of over 14,000 men with prostate cancer treated at 40+ sites. At UCSF, we have developed a novel program in clinical management of and research on active surveillance for men with low-burden prostate cancer. We are committed to reducing the burden of prostate cancer treatment (physical, psychological and monetary). In 2007, I and colleagues initiated the Prostate Cancer Active Surveillance Study (PASS), a large multi-institutional cohort of men on active surveillance, designed to examine quantitative metabolic, molecular, and physiologic imaging biomarkers and lifestyle factors as novel predictors of prostate cancer progression. We aim to better determine which patients may safely avoid radical treatment, while concurrently identifying men who may benefit from early treatment instead of active surveillance.

Education

University of California, Berkeley, BA, 1974, Zoology
Georgetown University School of Medicine, Washington, D.C., MD, 1979, Medicine
University of California, Berkeley, MPH, 2008
 


Professional Experience

  • 1984-1986
    Fellow, Urology Service, Memorial Sloan-Kettering Cancer Center
  • 1986-1992
    Assistant Professor in Residence, Dept. of Urology, University of California, S.F
  • 1992-1993
    Associate Professor, Dept. of Urology, University of California, San Francisco
  • 1996-present
    Program Leader, Program in Urologic Oncology, UCSF Cancer Center
  • 1996-present
    Professor and Chair, Department of Urology, UCSF, San Francisco, CA
  • 2003-present
    Surgeon-in-Chief, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2006-present
    Associate Director of Clinical Services and Strategic Planning, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2006-present
    Associate Dean, UCSF School of Medicine

Honors & Awards

  • Other Experience and Professional Memberships
  • 2002-present
    American Urological Association, Prize Essay Committee (Chair)
  • 2002-2008
    American Urological Association, Update Series Advisory Committee (member)
  • 2001-present
    American Board of Urology, Trustee, President Elect (2006-2008)
  • 2001-present
    American College of Surgeons Commission on Cancer, AUA representative
  • 2000-present
    American Association of Genitourinary Surgeons, Site Committee
  • 2003-present
    American Association of Genitourinary Surgeons, Councilor
  • 2004-present
    ASCO Prostate Cancer Committee, Symposium Committee
  • 2004-present
    ASCO, Oncology Taskforce
  • 2005-present
    ASCO, Cancer Communications Committee, Roster of Cancer Experts
  • 2005-present
    American College of Radiology’s Appropriateness Criteria Expert Panel on Radiation Oncology-Prostate, AUA representative
  • 2006-present
    The Journal of Urology, Associate Editor
  • 2011 – present
    AUA Update, Editor
  • Honors:
  • 2001
    Ken and Donna Derr - Chevron Endowed Chair in Prostate Cancer
  • 2002
    Clinical Society of the American Association of Genitourinary Surgeons
  • 2004
    Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer
  • 2010
    AUA Eugene Fuller Triennial Prostate Award
  • 2010
    Society of Urologic Oncology Medal
  • 2014
    Barringer Medal, American Association of Genitourinary Surgeons

Selected Publications

  1. Balakrishnan AS, Cowan JE, Cooperberg MR, Shinohara K, Nguyen HG, Carroll PR. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance. J Urol. 2019 Apr 08; 101097JU0000000000000247.
    View on PubMed
  2. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Mar 28.
    View on PubMed
  3. Boreta L, Gadzinski AJ, Wu SY, Xu M, Greene K, Quanstrom K, Nguyen HG, Carroll PR, Hope TA, Feng FY. Location of recurrence by Gallium-68 PSMA-11 PET scan in prostate cancer patients eligible for salvage radiotherapy. Urology. 2019 Mar 27.
    View on PubMed
  4. Tang J, Zhong L, Paoli C, Paciorek A, Carroll P, Wilson L. Longitudinal Comparison of Patient-Level Outcomes and Costs Across Prostate Cancer Treatments With Urinary Problems. Am J Mens Health. 2019 Mar-Apr; 13(2):1557988319835326.
    View on PubMed
  5. Greenland NY, Zhang L, Cowan JE, Carroll PR, Stohr BA, Simko JP. Correlation of a Commercial Genomic Risk Classifier with Histologic Patterns in Prostate Cancer. J Urol. 2019 Feb 15; 101097JU0000000000000175.
    View on PubMed
  6. Carroll P. Editorial Comment. J Urol. 2019 Feb; 201(2):298-299.
    View on PubMed
  7. Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, Shinohara K, Carroll PR. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance. J Urol. 2019 Feb; 201(2):300-307.
    View on PubMed
  8. Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer Prostatic Dis. 2019 Jan 21.
    View on PubMed
  9. Kenfield SA, Van Blarigan EL, Ameli N, Lavaki E, Cedars B, Paciorek AT, Monroy C, Tantum LK, Newton RU, Signorell C, Suh JH, Zhang L, Cooperberg MR, Carroll PR, Chan JM. Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer. Eur Urol. 2019 Jan 09.
    View on PubMed
  10. Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW. Continued 5a-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. J Urol. 2019 Jan; 201(1):106-111.
    View on PubMed
  11. Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, Roach M, Westphalen AC, Feng FY, Carroll PR, Chang AJ, Hope TA. Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer. Urology. 2019 Mar; 125:154-162.
    View on PubMed
  12. Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Meta-analysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. J Nucl Med. 2018 Dec 07.
    View on PubMed
  13. Behr SC, Aggarwal R, Van Brocklin HF, Flavell RR, Geo K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer. J Nucl Med. 2018 Nov 21.
    View on PubMed
  14. Winters-Stone KM, Kenfield SA, Van Blarigan EL, Moe EL, Ramsdill JW, Daniel K, Macaire G, Paich K, Kessler ER, Kucuk O, Gillespie TW, Lyons KS, Beer TM, Broering JM, Carroll PR, Chan JM. Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2018 Nov 15; 7(11):e11257.
    View on PubMed
  15. Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst. 2018 Oct 13.
    View on PubMed
  16. Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, Carroll PR, Hope TA. Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. Radiology. 2018 Dec; 289(3):730-737.
    View on PubMed
  17. McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, Torkler P, Noerholm M, Skog J, Shore N, Andriole G, Thompson I, Carroll P. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. Eur Urol. 2018 Dec; 74(6):731-738.
    View on PubMed
  18. Leapman MS, Nguyen HG, Cowan JE, Xue L, Stohr B, Simko J, Cooperberg MR, Carroll PR. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. Eur Urol. 2018 Nov; 74(5):668-675.
    View on PubMed
  19. Schmidt B, Eapen RS, Cowan JE, Broering JM, Greene KL, Carroll PR, Cooperberg MR. Practice patterns of primary EBRT with and without ADT in prostate cancer treatment. Prostate Cancer Prostatic Dis. 2018 Aug 31.
    View on PubMed
  20. Carroll PR. USPTF Prostate Cancer Screening Recommendations-A Step in the Right Direction. JAMA Surg. 2018 Aug 01; 153(8):701-702.
    View on PubMed

Go to UCSF Profiles, powered by CTSI